Tresiba® FlexTouch® insulin degludec injection instructions for use, indicated for the treatment of adult type 2 diabetes mellitus
This document provides detailed instructions for using Tresiba® FlexTouch® insulin degludec injection to treat type 2 diabetes. It covers dosage, administration methods, precautions, and adverse reactions. The product is administered subcutaneously once daily, with dosage adjusted based on individual patient needs. It is not for intravenous or intramuscular use.
The document also includes information on potential side effects such as hypoglycemia, injection site reactions, and weight gain, along with guidance on managing these risks. It advises patients to rotate injection sites to reduce the risk of fat metabolism disorders and to monitor blood glucose levels closely during dose adjustments or when switching from other insulin therapies. This manual is written in Chinese.
| Active Ingredient | Insulin Degludec |
|---|---|
| Concentration | 100 U/ml |
| Volume per Pen | 3 ml |
| Dosage Form | Subcutaneous Injection |
| Storage Condition | Do not freeze |
Once daily, at any time of day, preferably at the same time each day.
Yes, it can be used in elderly patients (≥65 years).
Administer the missed dose immediately upon discovery, then continue with the regular daily schedule.
The most common side effect is hypoglycemia (low blood sugar).